<DOC>
	<DOCNO>NCT02057315</DOCNO>
	<brief_summary>This Phase Ib , 12-week , multi-center , randomize , double-blind , cross-over , placebo-controlled study evaluate efficacy safety ELS-M11 compare placebo 50 male female subject , age 18 65 year suffer recur moderate-severe migraine headache ( 2-8 per month ) . This study design describe efficacy safety ELS-M11 compare placebo .</brief_summary>
	<brief_title>Study Determine Efficacy Safety ELS-M11 Acute Migraine</brief_title>
	<detailed_description>Achelios develop ELS-M11 topical application acute treatment migraine event patient history migraine without aura . To eligible study , patient must one-year documented history migraine headache ( defined International Headache Society IHS ) , without aura , 2≤8 moderate severe migraine attack per month 2 month prior screen visit . The total duration study completion five migraine headache per subject maximum 12 week period follow 3-14 day Follow-Up Period .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Provide write informed consent Males female age 1865 read , write understand English Subject least one year document history migraine headache ( defined International headache Society IHS ) migraine definition , without aura , 2≤8 moderate severe migraine attack per month 2 month prior screen visit Is stable current standard nonopioid rescue medication least 2 month prior randomization Can distinguish migraine tension headache ( HA ) , 24 hour freedom HA migraine event Women childbearing potential must currently use willing use contraception ( 30 day prior start study medication 21 day take study medication ) Women nonchildbearing potential include female regardless age , function ovary current document tubal ligation [ Hatcher , 2004 ] bilateral oophorectomy total hysterectomy , postmenopausal females The subject able willing perform assessment procedure specify protocol , include ability learn follow instruction ePRO device Migraineurs take opioidbased rescue medication indication Subject history mild migraine event migraine usually resolve spontaneously less 2 hour Subject menstrual migraine Positive Drug Test Subject basilar hemiplegic migraine Subject 15 headachedays per month Subjects history facial allodynia Subject history vomit 30 % migraine episodes Self confinement bed rest 50 % migraine episode Subject great 50 year old age migraine onset Acute coronary syndrome ( i.e. , myocardial infarction unstable angina ) , stroke resuscitate cardiac arrest within past 3 month Severe congestive heart failure Systolic blood pressure ( sBP ) &gt; 160 mmHg diastolic blood pressure ( dBP ) &gt; 100 mmHg measure sit position Visit 1 Current active renal disease Any history pyelonephritis Evidence active liver disease Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) alkaline phosphatase &gt; 2 time upper limit reference range ( ULRR ) , total bilirubin &gt; 1.5 time ULRR Visit 1 Past history acute pancreatitis current triglycerides 4.56 mmol/L ( 400 mg/dL ) Visit 1 History malignancy within past 3 year , nonmelanoma skin cancer ( i.e. , basal superficial squamous cell carcinoma ) treat cervical cancer insitu Any plan major surgery perform study ( e.g. , coronary artery bypass surgery , abdominal aortic aneurysm repair , etc . ) Current lifethreatening condition Significant hypersensitivity NSAIDs ( e.g. , difficulty swallow breathing , tachycardia , anaphylaxis , angioedema skin reaction ) Pregnancy ( define positive urine pregnancy test ) lactation Visit 1 , plan become pregnant prior completion study History suspicion alcohol substance abuse ( current past 6 month ) . Participation clinical trial within 30 day prior Visit 1 Subjects history hypersensitivity product contain tiaprofenic acid , suprofen , fenofibrate , oxybenzone , octocrylene ( e.g. , sunscreen , perfume ) Subjects history photosensitivity Any clinically significant abnormality reason subject may able complete full study observational period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Migraine headache</keyword>
	<keyword>Photophobia</keyword>
	<keyword>Phonophobia</keyword>
	<keyword>Aura</keyword>
	<keyword>Topical treatment</keyword>
</DOC>